Medicines Advisory Committee

Term

1 January 2021 - 31 December 2023

Scope

The Medicines Advisory Committee (MAC) provides advice to HPRG, including:

• Quality, safety and efficacy of medicines for marketing authorisation.
• Continued safety and effectiveness of medicines after marketing authorisation.
• Public interest consideration for marketing authorisation of medicines.
• Clinical consideration on the use of investigational drugs in clinical trials.
• Regulatory policies related to clinical use or supply of medicines.

Committee members

• Prof Fong Kok Yong (Chairman)
• Dr Khoo Kei Siong (Deputy Chairman)
• Assoc Prof Chan Cheng Leng (Secretary)
• Dr Camilla Wong
• Prof Philip Choo
• Prof Chua Hong Choon
• Dr Leong Hoe Nam
• Assoc Prof Lim Yean Teng
• Assoc Prof Sum Chee Fang
• Prof Tan Chee Kiat
• Dr Shen Liang

Medical Devices Advisory Committee

Term

1 January 2021 - 31 December 2023

Scope

The Medical Devices Advisory Committee (MDAC) provides advice to HPRG, including:

• Quality, safety, efficacy and/or performance of medical devices for marketing authorisation.
• Continued safety and effectiveness of medical devices after marketing authorisation.
• Public interest consideration for marketing authorisation of medical devices.
• Regulatory policies related to clinical use or supply of medical devices.

Committee members

• Prof Tan Huay Cheem (Chairman)
• Assoc Prof Chan Cheng Leng (Secretary)
• Assoc Prof Raymond Lin
• Assoc Prof Joyce Koh
• Dr Martin H'ng Weng Chin
• Assoc Prof Kenny Sin Yoong Kong
• Assoc Prof Patrick Tseng
• Assoc Prof Adrian Koh
• Prof Ho Khek Yu

Complementary Health Products Advisory Committee

Term

1 January 2021 - 31 December 2023

Scope

The Complementary Health Products Advisory Committee (CHPAC) provides advice to HPRG, including:

• Quality and safety of complementary health products for local supply.
• Continued quality and safety of complementary health products after local supply.
• Public interest and/or other considerations for local supply of complementary health products.
• Considerations on the use of investigational complementary health products in clinical trials.
• Regulatory policies related to the use and supply of complementary health products.

Committee members

• Prof Chin Jing Jih (Chairman)
• Adj Assoc Prof Kong Keng He (Deputy Chairman)
• Ms Lee Hui Keng (Secretary)
• Ms Chan Soo Chung
• Dr Cheng Sim Kim
• Prof Christiani Jeyakumar Henry
• Assoc Prof Koh Hwee Ling
• Ms Kwek Mei Lin
• Dr Joel Lee
  
  

Product Vigilance Advisory Committee

Term

1 August 2020 - 31 July 2023

Scope

The Product Vigilance Advisory Committee (PVAC) provides scientific advice to HPRG in relation to the continued availability and safe use of health products in Singapore, through the following:

• To review the benefit-risk profile of health products, assess the impact of significant safety issues associated with health products and advise on the appropriate regulatory actions to be taken to minimise the risk associated with the use of these products.
• To review serious selected adverse event reports, and advise on the causality assessment and appropriate follow-up actions to be initiated by HSA.
• To provide guidance on innovative post-marketing surveillance tools.
• To be an advocate of health products vigilance and actively promote adverse event reporting by healthcare professionals.
• To contribute to HSA’s educational programmes on health product safety in Singapore.

Committee members

• Prof Goh Chee Leok (Chairman)
• Assoc Prof Sum Chee Fang (Deputy Chairman)
• Ms Jalene Poh (Secretary - Health Sciences Authority)
• Prof Edmund Lee
• Dr Shen Liang
• Assoc Prof Chow Wan Cheng
• Adj Assoc Prof Bernard Thong
• Dr Derrick Heng
• Asst Prof Lim Toon Wei
• Dr Tan Lip Kun
• Asst Prof Tan Tze Lee
• Dr Camilla Wong
• Dr Belinda Lee

Panel of Advisors for the HSA Proficiency Testing (PT) Programme in Chemical Testing

Term

1 April 2019 - 31 March 2021

Scope

The Panel of Advisors for the HSA Proficiency Testing (PT) Programme in Chemical Testing provides advice to ASG, including:

• Issues that the Panel considers to be of major strategic significance to the PT programme.
• Choice of the test materials, analytes and their concentration ranges.
• Frequency of the programme.
• Design and implementation of the programme.
• Methods of evaluation of results.
• Comment on contents of reports.
• Interpretation of the performance of participating laboratories.

Committee members

• Adj Asst Prof Chan Sheot Harn (Chairperson)
• Dr Li Sihai
• Dr Zhang Lifeng
• Mrs Jeanette Wong
• Ms Low Min Yong

Panel of Advisors for the HSA External Quality Assessment (EQA) Programme in Clinical Chemistry

Term

1 April 2019 - 31 March 2022

Scope

The Panel of Advisors for the HSA External Quality Assessment (EQA) Programme in Clinical Chemistry provides advice to ASG, including:

• Issues that the Panel considers to be of major strategic significance to the EQA programme.
• Choice of the test materials, analytes and their concentration ranges.
• Frequency of the programme.
• Design and implementation of the programme.
• Methods of evaluation of results.
• Comment on contents of reports.
• Interpretation of the performance of participating laboratories.

Committee members

• Assoc Prof Wong Moh Sim (Chairperson)
• Dr Ho Han Kwee
• Assoc Prof Yeo Chin Pin
• Dr Lam Choong Weng Leslie
• Dr Loh Tze Ping